A number of anti-inflammatory and other drugs used in the treatment of rheumatoid arthritis have been screened for their ability to cause oxidative damage to lipids and proteins in vitro. Although many drugs exhibited an antioxidant profile, a few drugs tested were pro-oxidant, increasing peroxidation of arachidonic acid by mixtures of haem proteins and H202. This system may be an appropriate model to use in the inflammatory situation, since microbleeding to release haemoglobin occurs in the inflamed rheumatoid joint, where H 2 0 2 is produced by invading neutrophils.
overgrowth known as the pannus and the whole joint becomes inflamed and swollen, particularly during acute phases of the disorder when there may be bleeding into the synovial fluid within the joint capsule. As the disease progresses, the joint becomes increasingly immobile and eventually all joint function may be lost with fusion of the bones across the joint. The disease has no identifiable cause, although an autoimmune reaction has long been suspected as the disease does not affect single joints, with most of the major joints affected bilaterally.
Treatment for the disease is targeted at both the inflammatory and proliferative aspects of the disorder, consisting of non-steroidal anti-inflammatory drugs (NSAID) and corticosteroids respectively, although recently cytotoxic immunosuppressants such as methotrexate have been introduced (Table 1) . Second-line agents such as gold thiols can also be effective in some patients.
A major limitation on the use of NSAID in the treatment of rheumatoid arthritis (RA) is the incidence of side-effects. For example, phenylbutazone was one of the first NSAID to be introduced in the 1950s. Although it is effective in treating the symptoms of RA [I] , it can produce serious side-effects which include fluid retention, aplastic anaemia and agranulocytosis, which have resulted in the withdrawal of this drug from clinical use for RA. Despite this, phenylbutazone is still widely sold 'over the counter' in many countries. probably by a mechanism similar to the iron-catalysed Haber-Weiss reaction:
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The interaction of NO' and 02*-can also be dangerous [2O] . The product, peroxynitrite, is not only directly toxic, e.g. by oxidizing methionine and protein sulphydryl groups, but also breaks down to generate multiple toxic products including nitrogen dioxide gas (NO,'), OH' and nitronium ion (NO, +) [20, 21] . Table 2 . Evidence consistent with increased oxidative stress in rheumatoid arthritis.
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Increased lipid peroxidation products in serum and synovial fluid. swelling by inhibiting cyclo-oxygenase in the case of NSAID) but actually exacerbate oxidative damage to the tissues. Such damage could be responsible for, or contribute to, the side-effects observed with several drugs used in the treatment of RA.
Effects of drugs on oxidative damage to lipids and proteins
In the inflamed joint, haemoglobin liberated by microbleeding might interact with H202 formed by activated phagocytes to produce damaging oxidants [37-391. Addition of H202 to solutions of oxy-, deoxy-and met-haemoglobin results in the formation of a ferry1 species in which the oxidation state of the haem iron is thought to be raised to + I V and a free radical (possibly a tyrosine radical) is generated on the protein [40]. This property is shared by myoglobin, which is more often used in drug oxidation studies as there is less tendency for protein precipitation to occur. Oxidation of the iron in the haem groups of these two proteins by H 2 0 2 causes changes in the visible spectrum of the proteins (Fig. 1) and the ferryl derivatives are oxidants which stimulate lipid peroxidation using arachidonic acid as a substrate ( Table 3 , lines 1 and 2). Although activated haem proteins are not such powerful oxidants as the hydroxyl radical, they are extremely stable and the ferryl spectrum is detectable for several hours. Ferrylhaem species could be present in the inflamed joint and interact with any drugs administered.
As part of our extensive studies on RA, we have determined the influence of drugs used in the treatment of RA upon oxidative damage induced by haem protein/H202 or ferryl systems. Damage to arachidonic acid was used as a primary screen to detect drugs able to stimulate peroxidative damage. Such drugs were then studied in more detail, with damage to both lipids and proteins investigated. al-Antiproteinase was used as a target molecule for protein damage, being an important inhibitor of serine proteinases (especially elastase) in human body fluids, yet highly susceptible to oxidative inactivation, thus accelerating proteolytic damage at sites of injury [41] . We show additionally that the mitochondrial protein cytochrome c can promote oxidative damage to lipids and proteins in the presence of certain drugs; this is a potential mechanism by which drugs could cause mitochondrial damage in vivo. Cytochrome c is also easily released from damaged mitochondria and so could exert pro-oxidant effects at other sites.
Effect of drugs on in vitro lipid peroxidation
A wide range of drugs has been screened for their ability to exert pro-oxidant effects on lipid peroxidation using myoglobin/H202/arachidonic acid as a test system. A mixture of myoglobin and H Z 0 2 causes peroxidation of arachidonic acid ( Table 3 ) and this peroxidation may theoretically be accelerated, decreased or unaffected in the presence of drugs. Ability to decrease peroxidation may indicate a beneficial antioxidant action of the drug, whereas drugs which accentuate peroxidation could exacerbate oxidative damage in vivo. Drugs were screened at concentrations in the range 50-1000 pM (Table 4) . Most had no effect on lipid peroxidation at the concentrations tested and some were inhibitory. However, a significant stimulation of lipid peroxidation was observed with phenylbutazone, flufenamic and meclofenamic acids, which was maximal at about 500 pM concentration for phenylbutazone and around 200 pM for the fenamic acids, diminishing at higher concentrations (data shown in Table 3 ). Control experiments showed that none of these drugs interfered with the assay used to measure the peroxidation, nor did the drugs themselves generate a chromogen in the assay. The peroxidation induced by phenylbutazone was inhibited by a number of antioxidants, including the iron chelator desferrioxamine and ascorbic acid, and to a lesser (Table 5 ). These molecules may be preferentially oxidized by activated haem proteins [42-441. Peroxidation was not significantly inhibited by addition of superoxide dismutase (SOD) (500 units/ml), but chain-breaking antioxidants such as trolox C and butylated hydroxytoluene were inhibitory.
Addition of phenylbutazone or one of the fenamic acids at the optimum concentration causes a loss of the myoglobin ferry1 spectrum, confirming that these drugs are interacting with H202-activated myoglobin (Fig. 1) .
Effect of drugs on myoglobin-H202-dependent inactivation of a I -antiproteinase
The haem protein-H202 system can cause oxidative damage not only to lipids but also to proteins. Since protein damage is an important consequence of oxidative stress in vivo, we examined the effect of drugs on this process, using a,-antiproteinase as a model system. The activity of al-antiproteinase was measured by its ability to inhibit the serine proteinase elastase [41]. Phenyl- Table 5 . Effect of antioxidants on phenylbutazone-stimulated arachidonic acid peroxidation. Experimental conditions are as described in Table 3 . The following concentrations were used in the assays: phenylbutazone (PB) (500 pM), cysteine, butylated hydroxytoluene (BHT) and trolox C (5 mM), ascorbate and desferrioxamine (DFO) (500 pM), and SOD (500 unitdml). Concentrations quoted are the final concentrations in the reaction mixture. PB alone gave no chromogen in the TBA test, nor did it have any effect when added at the end with the TBA reagents. 
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butazone had an inhibitory effect on elastase but neither flufenamic nor meclofenamic acid had any significant effect on elastase alone ( Table 6 , column 1) although flufenamic acid slightly decreased the ability of al-antiproteinase to inhibit elastase (Table 6 , column 2, line 4). However, mixtures of the three drugs with myoglobin and H202 caused much greater decreases in the elastase-inhibitory capacity of a,-antiproteinase, seen as rises in the elastase activity measured. Damage to al-antiproteinase could be prevented by adding 1 mM ascorbic acid ( Table 6 , column 3).
Cytochrome c-dependent lipid peroxidation
Several drugs in therapeutic use induce mitochondrial damage [45], so it was of interest to see whether the abundant mitochondrial haem protein cytochrome c could catalyse the formation of damaging drug-derived species. Cytochrome c plus H202 induced some peroxidation of arachidonic acid ( Table 7) , as expected [46,47]. Addition of phenylbutazone or (to a lesser extent) meclofenamic acid, but not flufenamic acid, stimulated the peroxidation caused by cytochrome c. Purification of commercial cytochrome c by gel filtration on a Sephadex G25 column to remove any contaminating haem peptides did not affect its ability to stimulate lipid peroxidation. As a further control, commercial microperoxidase did not cause lipid peroxidation in the presence of H202. Cytochrome c-dependent peroxidation, with or without drugs present, was inhibited by ascorbic acid.
Cytochrome c could also promote protein damage, in that al-antiproteinase was inactivated by mixtures of cytochrome c, H202 and phenylbutazone In the presence of H202 and haem proteins, meclofenamic acid, flufenamic acid and phenylbutazone are oxidized to species that can accelerate lipid peroxidation and protein damage. Phenylbutazone was the most damaging drug examined, although the concentration required to give the maximum damage (500 pM) is greater than that required for the fenamic acids (200 pM). Damage to arachidonic acid is still, however, observed at lower concentrations. All three drugs are NSAID, and microbleeding which releases haemoglobin often accompanies both acute and chronic inflammation. Oxidative damage also occurs by interaction of phenylbutazone and meclofenamic acid with mixtures of cytochrome c and H202. Presumably the activated haem species oxidizes the drug to a radical while the haem iron is reduced. Fig. 1 indicates that the ferry1 spectrum of myoglobin reverts to the free metmyoglobin spectrum on addition of the drug. Electron spin resonance (ESR) studies on mixtures of myoglobin, H202 and phenylbutazone to which has been added the spin trap 5,5-dimethyl-I -pyrroline N-oxide (DMPO) yield complex ESR signals which are probably a mixture of the spectra of the DMPO-adducts of several radical species. No spectra are observed in the absence of the spin trap, presum- ably since the lifetimes of the radicals are too short. A phenylbutazone radical has been identified spectrophotometrically using pulse radiolysis during which a solution of phenylbutazone was bombarded with hydroxyl radicals (P. J. Evans and 0.1. Aruoma, unpublished work) . It is therefore likely that these ferry1 systems oxidize the drugs to free radical forms which cause the oxidative damage to arachidonic acid and al-antiproteinase.
Respiring mitochondria generate both H 2 0 2 and 02*- [45] . Thus cytochrome c-dependent oxidation of drugs could be a mechanism of drug-induced mitochondrial injury. In addition, damaged mitochondria at sites of tissue injury can leak cytochrome c and so could cause extramitochondrial oxidative damage. Damage by these haem protein-H202 systems to al-antiproteinase was used as a model system for ability to cause protein damage in our experiments. It is also clinically relevant since a,-antiproteinase has an exposed methionine group which is sensitive to oxidative damage and, as a major inhibitor of serine proteinases, has a protective effect on both structural and functional extracellular proteins. Damage to al-antiproteinase, apparently by free radicals, has been detected in the rheumatoid joint [48] and the generation of radicals from anti-inflammatory drugs could exacerbate this.
Addition of antioxidants such as ascorbic acid and trolox C to assays of lipid peroxidation and protein damage causes a decrease in the damage, possibly due to the activated haem species being reduced back to the lower oxidation state by ascorbate or trolox C in preference to oxidation of the drug or to scavenging of the protein-derived radicals by these substances. An additional explanation is that 8.
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